Changing Of The Guard At Merck KGaA With Garijo Succeeding Oschmann As CEO
Ensures Smooth Leadership Transition
The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.
You may also be interested in...
Join us for an audio roundup of major events in the international biopharma industry over the past week, as reported by Scrip's global team.
Expanding on difficult conversations during the recent BIO Digital meeting, the group aims to take actions that will increase diversity and inclusion in health care, science and industry.
After buying BlueRock Therapeutics outright last year, the Leverkusen-headquartered group has put down $2bn up front to acquire another cell and gene therapy specialist in Asklepios BioPharmaceutical.